Group 1 - The 420 Investor service, focused on cannabis stocks, has transitioned to Seeking Alpha, enhancing its coverage of the sector with model portfolios, videos, and written materials to assist investors [1] - Canopy Growth (CGC) has been under observation since its public listing, with a recent upgrade from Strong Sell to Hold, indicating a positive market response as the stock has rallied [1] - Alan Brochstein, a pioneer in cannabis investment analysis, has been managing the 420 Investor group since 2013, closely monitoring 19 cannabis stocks and providing timely investment news and earnings report analyses [1] Group 2 - The 420 Investor group features a model portfolio, 10 weekly videos with chart analysis, three summary pieces each week, a monthly newsletter, and a chat function for investor inquiries [1]

McEwen Inc. (NYSE:MUX) is one of the 9 Best Junior Gold Mining Stocks to Buy Now. On January 6, McEwen Inc. (NYSE:MUX) completed its acquisition of Canadian Gold Corp. (CGC) under a statutory plan of arrangement, as previously announced. Under the agreed terms, each Canadian Gold share will convert into 0.0225 MUX common shares, consolidating CGC holders into MUX books. Whereas, Canadian Gold will be delisted from the TSX Venture on January 7, 2026. Following the closing of the arrangement agreement on ...

Market Analysis by covering: Canopy Growth Corp, Tilray Inc. Read 's Market Analysis on Investing.com ...

Industry Overview - Cannabis stocks, including Canopy Growth and Aurora Cannabis, have seen a decline over the past five years despite initial popularity [1] - Recent regulatory changes, specifically President Trump's executive order rescheduling cannabis from Schedule 1 to Schedule 3, may provide new opportunities for the industry [3][4] Regulatory Changes - Cannabis is now classified as a Schedule 3 drug, indicating accepted medical benefits and lower potential for abuse compared to Schedule 1 and 2 substances [4] - This change could facilitate easier access to banking services and allow cannabis companies to deduct normal business expenses, potentially leading to increased revenue and profits [6] Company-Specific Insights - Canopy Growth has a market cap of $407 million, with a current price of $1.19 and a gross margin of 18.74% [5][6] - Aurora Cannabis has a market cap of $255 million, with a current price of $4.49 and a gross margin of -86.45% [8][9] - Despite the potential market size in the U.S., both companies face significant challenges, including federal illegality and competition [7][10] Market Challenges - Cannabis remains illegal at the federal level in the U.S., complicating interstate commerce for growers [7] - Aurora Cannabis lacks a retail or distribution presence in the U.S., which may hinder its ability to capitalize on market opportunities [7][9] - Canopy Growth, while having a subsidiary in the U.S., still faces similar federal and competitive challenges [10]

Core Insights - The article presents a series of interviews with millionaires discussing their strategies for accumulating wealth, emphasizing the importance of saving, investing, and living below one's means. Group 1: Wealth Accumulation Strategies - Many millionaires attribute their wealth to consistent savings and living below their income, with one individual noting that their net worth grew from $0 to $100,000 over several years through disciplined saving and investing [8][10]. - A significant number of interviewees highlight the importance of investing early and regularly, with one millionaire stating that 50% of their wealth accumulation was due to investments and the other half from hard work [7]. - Several millionaires emphasize the role of education and scholarships in reducing costs, with one family managing to secure full scholarships for their children, which significantly impacted their financial situation [5][14]. Group 2: Investment Approaches - Many interviewees recommend investing in low-cost index funds and maximizing contributions to retirement accounts such as 401(k)s and IRAs, with one individual noting that they have always fully funded their 401(k) as a non-negotiable priority [30][49]. - Real estate investments are mentioned as a key component of wealth accumulation, with one millionaire stating that they bought properties during a market dip, leading to significant gains over time [38]. - The importance of maintaining a disciplined investment strategy, regardless of market volatility, is highlighted, with one individual noting that they have consistently invested in mutual funds and ignored market noise [16][39]. Group 3: Personal Financial Management - The interviewees stress the importance of budgeting and tracking expenses, with one millionaire mentioning the use of spreadsheets to monitor net worth and savings goals [4][25]. - Living modestly and prioritizing experiences over material possessions is a common theme, with several individuals noting that they found joy in low-cost activities rather than spending on luxury items [7][11]. - The impact of inheritance on wealth accumulation varies, with some individuals benefiting from inheritances while others emphasize that their wealth is entirely self-made through hard work and smart financial decisions [20][34].

Group 1: Canopy Growth and MTL Acquisition - Canopy Growth's CEO Luc Mongeau emphasizes that MTL's cultivation expertise, combined with Canopy's scale, will enhance product quality, expand supply, and accelerate profitable growth [1] - Under the acquisition agreement, MTL shareholders will receive 0.32 of a common share of Canopy Growth and 14.4 cents in cash for each MTL share [1] - Canopy shares closed at $2.40 on the Toronto Stock Exchange on the day of the announcement [1] Group 2: BlackBerry Financial Performance - BlackBerry reported a third-quarter profit of US$13.7 million, a significant improvement from a loss of US$10.5 million in the same period last year [4][7] - The company's revenue for the third quarter was US$141.8 million, a slight decrease from US$143.6 million year-over-year [5][7] - The QNX segment achieved record revenue of US$68.7 million, reflecting a 10% increase from US$62.3 million a year earlier [5] Group 3: Transat A.T. Financial Performance - Transat A.T. reported a loss of $12.5 million in its fourth quarter, contrasting with a profit of $41.2 million in the same quarter last year [10][13] - Revenue for the fourth quarter totaled $771.6 million, down from $788.8 million a year ago, although revenue increased by 1.5% when excluding prior compensation related to Pratt & Whitney GTF engine issues [11] - On an adjusted basis, Transat reported a loss of 42 cents per share compared to an adjusted profit of 81 cents per share in the same quarter last year [12]

Core Viewpoint - President Donald Trump's executive order marks a significant shift in federal cannabis policy, directing federal agencies to loosen regulations on marijuana [1] Regulatory Changes - The order instructs U.S. Attorney General Pam Bondi to expedite the rescheduling of marijuana to Schedule III under the Controlled Substances Act, aligning it with common painkillers but not fully legalizing it [2] - Marijuana's current classification as a Schedule I substance has limited research opportunities, and reclassification aims to enhance studies on safety and effectiveness, particularly for vulnerable populations [4] Access to CBD Products - The order outlines steps to improve access to hemp-derived cannabinoid products, especially cannabidiol (CBD), which currently lacks a clear regulatory pathway through the FDA [5] - It directs the White House Deputy Chief of Staff to collaborate with Congress to expand access to full-spectrum CBD products while restricting those posing health risks [6] Political Reactions - Senate Minority Leader Chuck Schumer supports the order, viewing it as a positive step, but emphasizes the need for further decriminalization and easing banking regulations for the cannabis industry [7] - Conversely, some Republican senators, including Ted Budd, criticize the order as shortsighted and potentially harmful to youth [7][8] Market Reactions - Cannabis stocks initially surged following the announcement but retreated by the close, attributed to the lack of expected cannabis banking provisions in the order [9] - Despite the retreat, major cannabis stocks have seen significant gains throughout the month in anticipation of the executive order [11]

Core Viewpoint - Canopy Growth (CGC) shares have experienced a significant increase due to anticipated federal initiatives, including the reclassification of cannabis as a "Schedule III" drug and a potential Medicare pilot program for seniors [1][3]. Group 1: Stock Performance - CGC shares have risen by 90% compared to their low in late November [2]. - The stock is currently trading above its major moving averages (50-day, 100-day, 200-day), indicating bullish momentum as the company approaches 2026 [4]. Group 2: Federal Initiatives - The expected federal initiatives are likely to be transformative for cannabis stocks, facilitating institutional investments and easing tax burdens and banking restrictions, which could enhance revenue potential for CGC [3]. Group 3: Financial Strength - In the latest quarter, CGC narrowed its adjusted EBITDA loss to $3 million, reflecting positive momentum in the Canadian adult-use market [5]. - The company has approximately $300 million in liquidity, positioning it well for growth initiatives without immediate financial pressure [5]. Group 4: Strategic Acquisitions - Canopy Growth's recent acquisition of MTL Cannabis for about $179 million is expected to increase its domestic market share and contribute high-margin revenue [4]. Group 5: Historical Performance - CGC stock has historically performed well at the beginning of the year, averaging a 12% increase in January since 2015, supporting the case for maintaining exposure to the stock heading into 2026 [6][7].

Group 1: Toro Co Performance - Toro Co reported quarterly earnings of 91 cents per share, exceeding the analyst consensus estimate of 87 cents per share [1] - The company achieved quarterly sales of $1.066 billion, surpassing the analyst consensus estimate of $1.048 billion [1] - Following the earnings report, Toro's shares rose by 7% to $77.82 [1] Group 2: Other Notable Stock Movements - DBV Technologies SA shares increased by 35.5% to $24.36 after meeting primary endpoints in the Phase 3 VITESSE trial [3] - Udemy Inc gained 26.5% to $6.79 due to an all-stock merger agreement with Coursera [3] - Kodiak Sciences Inc jumped 16.7% to $28.16 after announcing a public offering of common stock [3] - Hut 8 Corp rose 16.3% to $42.88 following a partnership to accelerate AI infrastructure deployment and a $7.0 billion lease agreement [3] - Canopy Growth Corp increased by 16.2% to $2.13 amid reports of potential reclassification of marijuana [3] - Recursion Pharmaceuticals Inc gained 13.2% to $4.76 after an upgrade from JP Morgan [3] - Two Harbors Investment Corp surged 13.2% to $11.21 due to an acquisition announcement [3] - Quantumscape Corp gained 7.7% to $11.66 after signing a joint development agreement with a top-10 global automaker [3] - Jabil Inc reported better-than-expected earnings, leading to a 7% increase in shares to $227.50 [3]

Core Viewpoint - The Trump administration is considering reclassifying marijuana from a Schedule I drug to a Schedule III drug, which would reduce restrictions and potentially enhance research opportunities in the cannabis industry [1][2]. Group 1: Market Performance - Shares of cannabis companies have seen significant increases following the news of potential reclassification, with notable jumps in stock prices since the announcement [3]. - Specific companies such as Tilray Brands Inc., Cresco Labs Inc., Canopy Growth Corp., Curaleaf Holdings Inc., and Trulieve Cannabis Corp. are highlighted as experiencing substantial stock performance improvements [4]. - For example, one company reported a five-day growth of 123.11% and a closing increase of 34.93% on Tuesday [5]. Group 2: Regulatory Context - Currently, marijuana is classified as a Schedule I drug, indicating it has no accepted medical use and a high potential for abuse, alongside substances like heroin and LSD [7]. - In contrast, Schedule III drugs, which include substances like anabolic steroids and ketamine, are considered to have a moderate to low potential for dependence [8]. - Reclassifying marijuana would not change its federal legality but would position it as less dangerous than Schedule II drugs, which include substances like cocaine and fentanyl [8]. Group 3: Historical Context - Despite the recent stock performance, cannabis stocks remain significantly lower than their highs in early 2021, during a peak period of excitement for marijuana reform [6].